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Abstract 
Interdigitating Dendritic Cell Sarcoma (IDCS) is a 
very uncommon neoplasm embedded in the group of 
histiocytic and dendritic cell neoplasms. IDCS is a 
diagnosis of exclusion, being mandatory the 
preclusion of follicular dendritic cell sarcoma, 
histiocytic sarcoma, melanoma, and metastases, 
among another neoplasm. The clinical course is 
aggressive. BRAF V600E has been reported in 
IDCS. 
Keywords 
Interdigitating Dendritic Cell Sarcoma; histiocytic 
and dendritic cell neoplasms; BRAF 
Clinics and pathology 
Disease 
Interdigitating Dendritic Cell Sarcoma (IDCS) is a 
very uncommon neoplasm embedded in the group of 
histiocytic and dendritic cell neoplasms. Only about 
100 cases have been reported in the literature 
(Saygin C et al., 2013). IDCS is derived from normal 
interdigitating dendritic cells (IDCs), whose role 
consists to present antigens to T cells and regulate 
cellular immune response (Saygin C et al., 2013; 
Lupato V 2016). An association between IDCSs and 
solid tumors or others hematologic malignancies 
(usually B-cell neoplasms) has been reported 
(Saygin C et al., 2013; Pokuri VK et al., 2015). 
Neoplastic cells typically express, intensively and 
diffusely, the S100 protein (Fachetti et al., 2017). 
This neoplasm arises mainly involving lymph nodes 
(as isolated mass); whereas extranodal sites, like 
liver, skin, lung or gastrointestinal tract are less 
common (Lupato V et al., 2016).  
The clinical course is aggressive; some series 
described a median survival of 9 months in 
disseminated cases (Saygin C et al., 2013).  
There is no standardized treatment.  Surgical 
resection, chemotherapy and/or radiotherapy are 
therapeutic options and the choice of one over the 
other depends on whether the disease is located or 
disseminated (Saygin C et al., 2013; Dalia S et al., 
2014). 
PATHOGENESIS The etiopathogenesis of IDCS 
remains unclear. Hematopoietic stem cells from 
bone marrow are the origin of IDCs, which are 
localized in T-zones of lymphoid organs. In addition 
migration of Langerhans cells to lymph nodes 
constitutes another etiology of IDCs (Wu L et al., 
2007). An infectious origin of IDCS (Epstein-Barr 
virus or human herpesvirus), like others dendritic 
cells (DCs) neoplasms, has been dismissed (Saygin 
C et al., 2013; Pokuri VK et al., 2015).  
Several studies mentioned the relationship between 
IDCS and a variety of malignant neoplasms 
(hematologic or not).  
In fact, it has been demonstrated the same clone 
origin of IDCS and low-grade B lymphomas, due 
probably to a transdifferentiation mechanism (where 
B cells changes phenotypically but remains its 
genotypic features); showing identical clonal 
immunoglobulin heavy chain (IGH) gene 
rearrangements (Fraser CR et al., 2009; Saygin C et 
al., 2013) 
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Epidemiology 
IDCS is an extremely rare malignancy. Saygin C et 
al reviewed 100 of IDCs cases, reporting a slightly 
male predominance, with the median age of 
diagnosis in 56 years. Regarding geographic 
distribution, Asian and the USA represents the 
majority of IDCS cases, being 40% and 32% 
respectively (Saygin C et al., 2013). 
Clinics 
In general, clinical presentation consists of a painful 
cervical or axillary mass; therefore isolated nodal 
involvement is the most frequent location of IDCS 
(47%) (Xue T et al., 2018; Saygin C et al., 2013). 
However, nodal and extranodal region or solitary 
extranodal site, have also been reported in 28% and 
25% of all cases respectively (Saygin C et al., 2013). 
Among extranodal lesions, 26% of them affect the 
liver, being the extranodal IDCS most common (Xue 
T et al., 2018); however lung, spleen, bone marrow 
and digestive system could also be affected (Pokuri 
VK et al., 2015). Systemic symptoms like fatigue, 
fever or weight are less common than others DCs 
neoplasms; even so they have been described in 
IDCS with nodal and extranodal disease (Saygin C 
et al., 2013). It has been reported that 13% of local 
recurrence and 39% of distant metastases 6 and 9 
months after initial salvage treatment, respectively. 
Lymph nodes (29%), liver (11%), lung (11%) and 
bone marrow (8%), represent usual sites affected by 
metastases (Saygin C et al., 2013). 
Pathology 
Neoplastic cells are since ovoid to a spindle, also 
shows abundant eosinophilic cytoplasm where we 
could found an important amount of endoplasmic 
reticula and mitochondria (Skala SL et al., 2018; Xue 
T et al., 2018). Frequently, cell borders are indistinct. 
The nuclei morphology is not uniform, and usually 
presents large-sized nucleoli (Xue T et al., 2018). 
Different growth patterns have been described, as 
sheets, nests, whorls or fascicles (Skala SL et al., 
2018). Less typical of sarcomas or carcinomas 
(except those with lymphoepithelial origin) is the 
presence of sheets of small lymphocytes among all 
the dendritic cells; being a histologic key of IDCS 
(Dalia S et al., 2014).  
IMMUNOPHENOTYPE Immunohistochemical 
studies are an important diagnostic tool since 
differential diagnosis represents one of the main 
issues of IDCS's management. However, there is no 
specific marker for IDCS (Xue T et al., 2018). IDCS 
cells characteristically express S100, vimentin, and 
CD68 (variable); whereas they are consistently 
negative for Langerhans cell histiocytic and 
follicular dendritic cell markers (CD1a, langerin, 
CD21, CD23, and CD35) (Lupato V et al., 2016). Ki-
67 proliferative index usually ranges between 0-
70%, with a median value of 10% (Saygin C et al., 
2013).  
DIAGNOSIS IDCS is a diagnosis of exclusion, 
being mandatory the preclusion of follicular 
dendritic cell sarcoma, histiocytic sarcoma, 
melanoma, and metastases, among another neoplasm 
(Facchetti F et al., 2017). Diagnosis requires several 
diagnostic tools, since clinic suspicious, 
immunophenotypic markers, histological features to 
imaging techniques. It is important to emphasize that 
initially 11% of IDCS are misdiagnosed as other 
malignancy (Saygin C et al., 2013). In terms of 
staging, computed tomography and bone marrow 
biopsy are usually performed (Pokuri VK et al., 
2015). Diagnostic features defining of IDCS are: 
expression of S100 and vimentin, a cell with 
dendritic processes and solitary cervical/axillary 
mass (Skala SL et al., 2018). 
Cytogenetics 
Nowadays it remains one of the areas around IDCS 
where further knowledge needs to be achieved. Thus 
there is no molecular finding specific of IDCS. IGH 
gene rearrangements have been reported in some 
IDCS cases similar to other histiocytic/dendritic cell 
neoplasms (Fraser CR et al., 2009). 
Genes 
BRAF V600E has also been reported in IDCS 
(O'Malley DP et al., 2015). Certainly, new 
techniques, such as next-generation sequencing 
(NGS), should be implemented to reach molecular 
advances. 
Treatment 
There is no consensus on treatment strategy. The 
vast majority of patients are treated by surgery with 
or without chemotherapy and/or radiotherapy (Xue 
T et al., 2018). Chemotherapy regimens usually used 
are ABVD (doxorubicin, bleomycin, vinblastine, 
dacarbazine), CHOP (cyclophosphamide, 
doxorubicin, vincristine, prednisone), ICE 
(ifosfamide, cisplatin, etoposide) or DHAP 
(dexamethasone, cisplatin, high dose of cytarabine) 
(Pokuri VK et al., 2015). Surgical resection and/or 
radiotherapy are the preferred option in localized 
IDCS; whereas chemotherapy is preferred in 
disseminated IDCS (Dalia S et al., 2014).  
Significantly better overall survival (OS) is seen in 
localized versus distant disease (Saygin C et al., 
2013; Perkins SM et al., 2013). In those limited 
disease cases, the therapeutic choice between 
surgery or non-surgery modalities continues to be 
debated. One study showed a statistically significant 
difference in OS with surgery (Perkins SM et al., 
2013) that could not be confirmed (Saygin C et al., 
2013).  
In disseminated cases chemotherapy is often used, 
indeed completes remissions in patients with IDCS 
have been reported with ABVD schemes (Helbig G 
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et al., 3015; Kyogoku C et al., 2015). Some authors 
recommend surgery with adjuvant chemotherapy, 
but further studies is needed to make stronger 
recommendations. 
Prognosis 
Prognostic factors associated with adverse outcomes 
(relapse and death) in IDCS are young age, intra-
abdominal disease and the combination of nodal and 
extranodal involvement (Saygin C et al., 2013). It 
has been proposed that the greater activity of antigen 
presentation in young people could explain their 
worse prognostic (Saygin C et al., 2013). The 
median survival in the group of patients with this 
diagnostic is of 9 months in metastatic disease local 
disease cases. In local disease, the survival rate after 
2 years of follow-up was 68% (Saygin C et al., 
2013). 
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